Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Teva
AstraZeneca
Merck
McKinsey
Daiichi Sankyo
Covington
Johnson and Johnson
Federal Trade Commission

Generated: October 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,893,097

« Back to Dashboard

Which drugs does patent 7,893,097 protect, and when does it expire?


Patent 7,893,097 protects NUVESSA and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 7,893,097

Title:Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water
Abstract: The combination of any two of a polyol, a polyol ether, and a low carbon organic alcohol provides a synergistic effect on the solubility of azole compounds, such as metronidazole, in aqueous fluid.
Inventor(s): Yang; Meidong (Richmond, CA), Chen; Haigang (Petaluma, CA)
Assignee: Dow Pharmaceutical Sciences, Inc. (Petaluma, CA)
Application Number:12/012,413
Patent Claim Types:
see list of patent claims
Formulation; Compound; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Chemo Research Sl
NUVESSA
metronidazole
GEL;VAGINAL205223-001Mar 24, 2014RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,893,097

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,658,678Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water► Subscribe
8,877,792Compositions for increasing solubility of azole drug compounds that are poorly soluble in water► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,893,097

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina070406► Subscribe
World Intellectual Property Organization (WIPO)2009097143► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
US Department of Justice
Cerilliant
US Army
Baxter
Fish and Richardson
Julphar
Queensland Health
Teva
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot